Abstract 1420P
Background
FGFR2b protein is emerging as a potential therapeutic target in patients with advanced GC/GEJC. This study investigated the estimated prevalence of FGFR2b protein overexpression and its overlap with actionable biomarkers.
Methods
Tumor samples from 130 Japanese patients diagnosed with advanced/metastatic GC/GEJC between 01 January 2021 and 31 October 2022 were analyzed. FFPE samples collected before 1L were tested via immunohistochemistry (IHC) for FGFR2b [clone FPR2-D] and PD-L1 [clone 28-8]. HER2, MMR and Claudin 18 [clone 43-14A] expression were also assessed. FGFR2b overexpression was defined as any percentage of tumor cells exhibiting moderate (2+) to strong (3+) membranous staining (FGFR2b any 2+/3+). FGFR2b overexpression of ≥10% of tumor cells exhibiting 2+ to 3+ membranous staining (FGFR2b ≥10% 2+/3+) was also evaluated.
Results
Estimated prevalence of FGFR2b any 2+/3+ was 29% (95% CI: 22, 39) and of FGFR2b ≥10% 2+/3+ was 11% (95% CI: 6, 17). In HER2 negative FGFR2b any 2+/3+ tumor samples, 16% exhibited a PD-L1 CPS ≥ 5 and 36% expressed Claudin 18 in ≥75% of tumor cells at 2+ or 3+ staining. For HER2 negative FGFR2b ≥10% 2+/3+ tumor samples, those proportions were 14% and 43%, respectively. Select biomarker overlap is summarized in the table. Table: 1420P
Overlap of HER2, PD-L1, MMR, Claudin 18, and FGFR2b in advanced or metastatic G/GEJ cancer tumor samples from a Japanese cohort
| Within HER2 Negative | ||||||
| Total | HER2 positive | HER2 negative | PD-L1 CPS ConclusionsThis real-world study estimated the prevalence of FGFR2b protein overexpression in GC/GEJC, revealing limited overlap with currently actionable biomarkers such as PD-L1 and Claudin 18 in tumor samples from a Japanese cohort. Clinical trial identificationEditorial acknowledgementLegal entity responsible for the studyAmgen Inc. FundingAmgen Inc. DisclosureS.L. Rhodes, E. Finger, C. Chang, R.E. Yanes, H. Honeycutt: Financial Interests, Personal, Full or part-time Employment: Amgen; Financial Interests, Personal, Stocks or ownership: Amgen. Y. Aoki: Financial Interests, Personal, Invited Speaker: Guardant Health Inc. I. Nakayama: Financial Interests, Institutional, Local PI: Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Company, Limited, MSD. Y. Nakamura: Financial Interests, Personal, Invited Speaker: Chugai, Merck Biopharma, Guardant Health Pte Ltd., MSD K.K, Eisai, Zeria Pharmaceutical, Miyarisan Pharmaceutical, CareNet, Inc., Hisamitsu Pharmaceutical, Taiho Pharmaceutical, Daiichi Sankyo Co., Ltd., Becton Dickinson, Guardant Health Japan Corp.; Financial Interests, Personal, Advisory Board: Natera, Inc., Roche Ltd., Seagen, Inc., Premo Partners, Inc., Daiichi Sankyo Co., Ltd., Takeda, Exact Sciences, Gilead Sciences, Guardant Health Pte Ltd; Financial Interests, Institutional, Funding: Taiho, Chugai, Guardant Health, Genomedia, Daiichi Sankyo, Roche Diagnostics, Guardant Health AMEA, Inc., Tempus; Financial Interests, Institutional, Coordinating PI: Seagen. A. Kawazoe: Financial Interests, Personal, Advisory Board: Zymeworks, Merck & Co.; Financial Interests, Personal, Invited Speaker: Taiho Pharmaceutical Co., Ltd., Daiichi Sankyo Company, Limited, Eli Lilly, Bristol Myers Squibb, Ono Pharmaceutical Co., Ltd. D. Kotani: Financial Interests, Personal, Invited Speaker: Bristol Myers Squibb, Chugai, Daiichi Sankyo, Eli Lilly, MSD, Merck Biopharma, Ono pharma, Pfizer, Taiho pharma, Takeda, Sysmex, Nihonkayaku, Novartis, Guardant Health; Financial Interests, Personal, Advisory Board: Takeda; Financial Interests, Institutional, Local PI: Ono pharma, MSD, Servier, Novartis, Janssen pharma, IQVIA, Syneos Health, CIMIC Shiftzero, CIMIC; Financial Interests, Institutional, Funding: Ono pharma. Y. Kuboki: Financial Interests, Personal, Advisory Board: Takeda, Amgen, Abbie, Incyte, Boehringer Ingelheim; Financial Interests, Personal, Invited Speaker: Taiho, Lilly; Financial Interests, Institutional, Local PI: Taiho, Astellas, Lilly, Takeda, AstraZeneca, Boehringer Ingelheim, Chugai, Genmab, Incyte, Abbie, Merck, Novartis, Hengrui; Financial Interests, Institutional, Coordinating PI: Amgen; Non-Financial Interests, Member: JSMO, ASCO, JSCO, JCA. H. Bando: Financial Interests, Institutional, Research Grant: Ono Pharmaceutical; Other, Lecture fee: Ono Pharmaceutical, Taiho Pharmaceutical, Eli Lilly Japan. T. Kojima: Financial Interests, Personal, Invited Speaker: MSD, Bristol Myers Squibb, Ono Pharmaceutical; Financial Interests, Personal, Advisory Board: Boehringer Ingelheim, Kyowa Kirin, Taiho Pharmaceutical; Financial Interests, Institutional, Local PI: AstraZeneca, BeiGene, MSD, Amgen, Chugai Pharmaceutical, Taiho Pharmaceutical, Shionogi Pharma, Amgen Astellas BioPharma. T. Yoshino: Financial Interests, Personal, Invited Speaker: Chugai Pharmaceutical Co., Ltd., Merck Biopharma Co., Ltd., Bayer Yakuhin, Ltd., Ono Pharmaceutical Co., Ltd., MSD K.K., Takeda Pharmaceutical Co., Ltd.; Financial Interests, Personal, Other, Consultancy: Sumitomo Corp.; Financial Interests, Institutional, Research Grant: Ono Pharmaceutical Co., Ltd., Sanofi K.K., MSD K.K., Taiho Pharmaceutical Co., Ltd., Molecular Health GmbH, Amgen K.K., Pfizer Japan Inc., Genomedia Inc., Sysmex Corp., Daiichi Sankyo Co., Ltd., Chugai Pharmaceutical Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., Eisai Co., Ltd., Roche Diagnostics K.K., FALCO Biosystems Ltd., Merus N.V., Bristol Myers Squibb K.K., Medical & Biological Laboratories Co., LTD., Takeda Pharmaceutical Co., Ltd. K. Shitara: Financial Interests, Personal, Advisory Board: Bristol Myers Squibb, Takeda, Ono Pharmaceutical, MSD, Novartis, Daiichi Sankyo, Amgen, Guardant Health Japan Corp, Astellas Pharma Inc., Astellas, Bayer, AstraZeneca, Zymeworks Biopharmaceuticals Inc., ALX Oncology Inc.; Financial Interests, Personal, Invited Speaker: Bristol Myers Squibb, Janssen, AstraZeneca, Eli Lilly, Astellas, Ono Pharmaceutical; Financial Interests, Institutional, Research Grant: Astellas, Ono Pharmaceutical, Daiichi Sankyo, Taiho Pharmaceutical, Chugai Pharmaceutical, MSD, Eisai, Amgen, PRA Health Sciences. All other authors have declared no conflicts of interest. Resources from the same session498P - Report of 9 cases of embryonal tumours of the central nervous system with multilayered rosettes (ETMR)Presenter: Ruyu Ai Session: Poster session 17 Resources: Abstract 499TiP - A phase II study of BPM31510 (a lipid nanodispersion of oxidized CoQ10) with vitamin K in combination with standard of care (SOC) RT and TMZ in glioblastoma multiforme (GBM) patients without prior therapyPresenter: Brian Stockdale Session: Poster session 17 500TiP - Update on GBM AGILE: A global, phase II/III adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastomaPresenter: Michael Weller Session: Poster session 17 501TiP - Clinical performance evaluation of a brain cancer liquid biopsyPresenter: James Cameron Session: Poster session 17 692P - Role of adjunctive surgery after platinum-based chemotherapy in management patients with adrenocortical carcinoma: Observation studyPresenter: Yaroslav Zhulikov Session: Poster session 17 693P - Causes of death in patients with malignant adrenal tumors: A population-based analysisPresenter: Shangqing Ren Session: Poster session 17 946P - Ipilimumab and nivolumab in advanced hepatocellular carcinoma after failure of prior atezolizumab and bevacizumab treatment: A multicenter retrospective studyPresenter: Jung Sun Kim Session: Poster session 17 948P - Drug type and duration of adjuvant immune checkpoint inhibitors in hepatocellular carcinoma with high-risk recurrence factors (PREVENT): An update analysis of a prospective, multicentric cohort studyPresenter: Jia-Yong Su Session: Poster session 17 Resources: Abstract 949P - Update results of ALTER-H006: A phase II study of TQB2450 plus anlotinib as adjuvant therapy in hepatocellular carcinoma (HCC) with high risk of recurrence after surgical resectionPresenter: Xianhai Mao Session: Poster session 17 950P - Outcomes by baseline tumour burden in EMERALD-1: A phase III, randomised, placebo (PBO)-controlled study of durvalumab (D) ± bevacizumab (B) with transarterial chemoembolisation (TACE) in participants (pts) with embolisation-eligible unresectable hepatocellular carcinoma (uHCC)Presenter: Masatoshi Kudo Session: Poster session 17 This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. For more detailed information on the cookies we use, please check our Privacy Policy.
| |||